Posters –
Infectious diseases and Vaccines
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Translational platform for addressing antibiotic resistance
Hilde Revets
University of Antwerp - VAXINFECTIO
- state-of-the-art high-and medium throughput in vitro biofilm models including
microcosm models
- clinically relevant animal models of S. aureus infection, namely, pneumonia/VAP and
acute endocarditis models for high content discovery compound screening
Technology
- expertise in studying the mechanism of biofilm and persister formation and the link with
virulence and antibiotic resistance
- next generation sequencing (NGS) platform to allow rapid identification of bacterial DNA
and RNA signatures and use as ‘track-and-trace’ system for antimicrobial resistance
- expertise in profiling drug resistance development in animal models upon treatment, as
well as biodistribution/tissue penetration and tissue toxicity analyses, thus allowing to
characterize the activities at the basis of a therapeutic compound and hereby helping to
predict potential side effects and/or failures of the treatment in humans.
Customers / Target market
Pharma and Biotech companies involved in the development of antimicrobial drugs (incl
vaccines) and Medical Device companies
Research Institutes involved in research on antimicrobial resistance
Industry : Pharma and Biotech Industry
Industry and competitors
Competitors : currently uniquely positioned as multidisciplinary platform
Financing need / Commercial
opportunity
Looking for:
- fee-for-service activities
- research contracts
IP – Patent situation
N/A
Future steps / Milestones
N/A
Further reading
N/A
Contact person
Dr. Hilde Revets, Research and Innovation Manager, Vaccine & Infectious Disease
Institute (VAXINFECTIO) – University of Antwerp, hilde.revets@uantwerpen.be